EGLE Therapeutics Strengthens its Board of Directors with the Appointment of Michel Detheux, Ph.D., as Independent Chairman Board Member, and with the Appointment of Mojgan Hossein-Nia, Ph.D. as Board Member Representative of Takeda Ventures
EGLE Therapeutics, a clinical-stage biotechnology company uniquely positioned to advance the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, announced today the appointment of Michel Detheux Ph.D, as Chairman of the Board and Independent Board Member, and Mojgan Hossein-Nia as Director representative of Takeda Ventures.
“We are thrilled to welcome Michel Detheux and Mojgan Hossein-Nia to our Board of Directors. Michel and Mojgan’s expertise and outstanding track record will be invaluable to Egle as we advance our clinical pipeline of novel therapies addressing the unmet medical need of patients with advanced cancer and autoimmune diseases.Their expertise in the field of oncology and their experience are instrumental for us to successfully execute on our strategic priorities,” said Vincent Brichard, M.D., EGLE’s Interim CEO and Board member.
“With the role of regulatory T cells becoming clearer in oncology and auto-immunity, I am excited to join the Board of Egle in order to help the team to move their differentiated pipeline toward a clinical proof of concept and help patients with innovative drugs targeting IL-2,” said Michel Detheux, independent chairman at Egle and CEO of iTeos Therapeutics.
“I am excited to join the Board of Egle in order to help the team strategize and continue to advance their pipeline to help patients in areas of unmet needs,” said Mojgan Hossein-Nia, Board Member at Egle Therapeutics.
Michel Detheux, Ph.D, Michel has held the role of Chief Executive Officer at iTeos Therapeutics since the company’s inception in 2012. During his tenure, Michel has led the company from its origins to NASDAQ listing, raising $335MM in 2020 through a crossover round and IPO. More recently, he spearheaded the strategic collaboration with GlaxoSmithKline in 2021 to co-develop and co-commercialize iTeos’ differentiated anti-TIGIT antibody for a total value of $2B. He previously served as a director at Ludwig Cancer Research and worked in various scientific and business development roles at Ogeda (f/k/a Euroscreen).
Dr. Detheux holds a degree of Bio-engineer and a Ph.D. in Biochemistry from Université Catholique de Louvain, and a business certificate from Solvay Business School.
Mojgan Hossein-Nia, Ph.D., Mojgan is the Head of R&D Global Portfolio Strategy and Strategic Finance, Research and Development at Takeda. She joined the company in September 2017 and currently directs portfolio strategy and management across all therapeutic areas facilitating investment decisions and overseeing R&D governance process. Additionally, she manages enabling capabilities that support portfolio management including the center of operational performance and integrated portfolio/finance digital solutions. In previous roles, she led the R&D investor relations group and built up the R&D Partnership Office, which was created to manage the overall health of R&D’s pipeline partnerships and their integration into R&D processes.
Before joining Takeda, Mojgan worked at Novartis Pharmaceuticals, building and leading multiple global functions across R&D. Mojgan’s career spans over 30 years, comprising dedicated roles in development outsourcing, global program leadership and project management, business development & licensing, and across multiple therapeutic areas including cardiovascular, metabolism, and cell & gene therapies.
Dr. Hossein-Nia holds a B.Sc, and Ph.D. in biochemistry from University of London, UK, and a diploma in pharmaceutical medicine from University of Surrey, UK.
About Egle Therapeutics SAS (Egle)
Egle Therapeutics is a biotechnology company focused on developing immunotherapies targeting suppressive regulatory T cells. Egle is leveraging a proprietary discovery platform to unveil novel Treg specific targets and to develop innovative Treg-focused drug candidates for oncology and autoimmune diseases. Egle aspires to advance toward the clinic its most advanced drug candidates, EGL-001 (a potential best-in-class Treg-selective anti-CTLA4-IL-2m) and EGL-003 (non-targeted IL-2 Treg engager), which are currently in IND-enabling studies.
Find out more at www.egle-tx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240912516511/en/
Contacts
contact@egle-tx.com / 0033 (0)1 86 64 08 57
contact@egle-tx.com / 0033 (0)1 86 64 08 57
investor.relations@egle-tx.com / 0033 (0)1 86 64 08 57
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TOURISE Awards 2025: Tokyo, New York, Ancash and Paris Take Top Honors at Inaugural TOURISE Awards12.11.2025 19:31:00 CET | Press release
The very first winners of the TOURISE Awards have been announced, recognizing the destinations redefining exploration, hospitality, and cultural connection for the modern traveler, setting new benchmarks for innovation and excellence to deliver truly unforgettable visitor experiences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112648089/en/ His Excellency Ahmed Al-Khateeb, Minister of Tourism and TOURISE Chairman, celebrates with the winners of the TOURISE Awards Taking place as part of the inaugural TOURISE Summit, held under the patronage of His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister, Tokyo, Japan, emerged as the big winner, clinching the coveted title of Best Overall Destination. In addition, Tokyo was also recognized as both the Best Food & Culinary and Best Entertainment destination, affirming its status as a global capital of innovation, energy, and unfor
Brenus Pharma Expands Its Global Scientific Advisory Board With Us Immuno-Oncology Expert Prof. Olivera J. Finn12.11.2025 19:00:00 CET | Press release
Brenus Pharma, a clinical-stage biotechnology company developing first-in-class in vivo immunotherapies for solid tumors, announced the appointment of Olivera J. Finn, Distinguished Professor at the University of Pittsburgh School of Medicine, to its Scientific Advisory Board (SAB). This strategic addition strengthens Brenus’ international SAB as the company advances its proprietary Stimulated Ghost Cell (SGC) platform and lead candidate STC-1010 toward its next clinical milestones. Globally recognized for her groundbreaking contributions to cancer immunology, Prof. Finn has led major discoveries in tumor antigens. She identified the MUC1 tumor antigen, a cornerstone in cancer research, and discovered cyclin B1 as a promising target for anti-cancer immunotherapy. Over her career, she has authored more than 220 peer-reviewed publications and co-led extensive clinical trials across pancreatic, colon, breast, prostate, and lung cancers. She also served as President of the American Associa
Telcoin Makes U.S. Banking History with Approval to Launch the First Regulated Digital Asset Bank12.11.2025 19:00:00 CET | Press release
Charter approval allows Telcoin Digital Asset Bank to establish a bridge between traditional banking and decentralized finance, including the creation of eUSD as the nation’s first bank-issued stablecoin. Telcoin today announced its final charter approval from the Nebraska Department of Banking and Finance to launch Telcoin Digital Asset Bank, the first Digital Asset Depository Institution in the United States. The charter positions Telcoin to become the first true blockchain bank, directly connecting U.S. bank accounts to regulated “Digital Cash” stablecoins. Its flagship product, eUSD, will be the first bank-issued, on-chain U.S. dollar stablecoin, offering consumers and businesses a secure, compliant way to use Digital Cash for payments, remittances, and savings. Notably, it is also the first bank charter to explicitly authorize connecting U.S. consumers to DeFi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112119122
Mindbreeze Named a Leader in the IDC MarketScape: Worldwide General-Purpose Knowledge Discovery Software 2025 Vendor Assessment12.11.2025 18:01:00 CET | Press release
Mindbreeze, a leading global provider of AI-based knowledge management solutions, has been named a Leader in the IDC MarketScape: Worldwide General-Purpose Knowledge Discovery Software 2025 Vendor Assessment (doc #US53011225, November 2025). In the IDC MarketScape 14 vendors of knowledge discovery software were evaluated. For the assessment, IDC divided potential key measures for success into two primary categories: capabilities and strategies. Get your complimentary copy of the excerpt here. The IDC MarketScape notes, “Companies looking for reliable, context-aware insights from internal and external sources should consider Mindbreeze. The platform enables decision making for compliance, risk management, and strategic planning, appealing to business areas such as customer service, finance, legal, and HR. It can tailor pre-built search applications to specific departments for search while supporting broader knowledge management and digital workspace initiatives.” "We are proud to be rec
Ardian Set to Mobilize Development Finance Institutions (DFIs) With European Investment Bank (EIB), Proparco and British International Investment (BII) for a €100m Commitment for Its Nature-Based Solutions Strategy12.11.2025 17:12:00 CET | Press release
Ardian’s Nature-Based Solutions strategy is dedicated to investing in projects in reforestation, wetlands and mangrove restoration intended to protect biodiversity. The strategy aims at providing carbon credit to corporates in their decarbonisation strategy. It will enable the sequestration of 85 million tons of carbon from the atmosphere over a 40 year’ period. European Investment Bank commits €50m and Proparco €20m and British International Investment intend to commit €10m, reflecting increasing DFIs appetite in the sector. Ardian, a world-leading private investment firm, today announces that it has secured commitment from several Development Finance Institutions (DFIs), the European Investment Bank (EIB) and Proparco. British International Investment (BII) have signaled their intention to provide commitment to the Nature Based Solutions fund. Total fund commitments will stand for a total of c. €100m by year end to Ardian’s Nature-Based Solutions (NBS) strategy. As anchor investors,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom